1-9 of 9
Thomas Prebet, M.D., Ph.D.
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Interim Results of A Randomized Phase II Trial of Azacitidine (AZA) +/− Epo In Lower Risk Myelodysplastic Syndrome (MDS) Resistant to An Erythropoietic Stimulating Agent (ESA) Alone

Simone Boehrer, MD, Odile Beyne-Rauzy, MD, Thomas Prebet, M.D., Ph.D., Sophie Park, MD, PhD, Agnès Guerci, MD, Aspasia Stamatoulas, MD, MP Chaury, MD, Tony Jernival, Laurence Sanhes, MD, Gerard Tertian, MD, Stephane Cheze, MD, Eng-Mong Lim, Bachra Choufi, MD, Denis Caillot, MD, E. Wattel, MD, Jacques Delaunay, MD, Laurence Legros, MD, Fatiha Chermat, Françoise Isnard, MD, N. Cambier, MD, Borhane Slama, MD, Lydia Roy, MD, Gandhi Damaj, MD, Emmanuel Raffoux, MD, Francois Dreyfus, MD, Christian Récher, MD, Norbert Vey, MD, Sylvie Chevret, PhD, Pierre Fenaux, MD, PhD, Claude Gardin, MD
Journal: Blood
Blood (2010) 116 (21): 1880.
https://doi.org/10.1182/blood.V116.21.1880.1880
Published: 2010
Journal Articles

Lenalidomide (LEN) In Lower-Risk Myelodysplastic Syndromes (MDS) with Karyotypes Other Than Deletion 5q and Refractory to Erythropoiesis-Stimulating Agents (ESAs)

David Sibon, Giovanna Cannas, Fiorenza Barraco, Thomas Prebet, M.D., Ph.D., Norbert Vey, MD, Anne Banos, MD, Caroline Besson, Selim Corm, Michel Blanc, Borhane Slama, Hervé Perrier, Pierre Fenaux, MD, PhD, Eric Wattel
Journal: Blood
Blood (2010) 116 (21): 4002.
https://doi.org/10.1182/blood.V116.21.4002.4002
Published: 2010
Journal Articles

A Phase I-II Study of Vorinostat and Low Dose Cytarabine for Patients Treated for High Risk Myelodysplastic with Azacytidine Failure: The GFM-VOR2007 Study

Thomas Prebet, M.D., Ph.D., Thorsten Braun, M.D., Ph.D., Odile Beyne Rauzy, Francois Dreyfus, Aspasia Stamatoullas, Eric Wattel, Shanti Ame, MD, Emmanuel Raffoux, MD, Jacques Delaunay, Celia Salanoubat, Isabelle Mathieu, Fatiha Chermat, Lionel Ades, Pierre Fenaux, MD, PhD, Norbert Vey, MD
Journal: Blood
Blood (2010) 116 (21): 4003.
https://doi.org/10.1182/blood.V116.21.4003.4003
Published: 2010
Journal Articles

Post-Transcriptional Deregulation of MYC Via PTEN Constitutes a Major Alternative Pathway of MYC Activation In T-Cell Acute Lymphoblastic Leukemia

Mélanie Bonnet, PhD, Marie Loosveld, Bertrand Montpellier, PhD, Jean-Marc Navarro, PhD, Benoit Quilichini, PhD, Christophe Picard, PhD, Julie Di Cristofaro, PhD, Chantal Fossat, PhD, Lucie Hernandez, PhD, Emilie Mamessier, PhD, Sandrine Roulland, Christine Formisano-Tréziny, PhD, Willem A Dik, PhD, Anton Langerak, Thomas Prebet, M.D., Ph.D., Norbert Vey, MD, Gérard Michel, Jean Gabert, MD, Jean Soulier, Elizabeth A. Macintyre, PhD, FRCP, FRCPath, Vahid Asnafi, Dominique Payet-Bornet, PhD, Bertrand Nadel
Journal: Blood
Blood (2010) 116 (21): 4188.
https://doi.org/10.1182/blood.V116.21.4188.4188
Published: 2010
Journal Articles

A 10 Day Schedule of Azacitidine Induces More Complete Cytogenetic Remissions Than the Standard Schedule In Myelodysplasia and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the E1905 US Leukemia Intergroup Study

Thomas Prebet, M.D., Ph.D., Zhuoxin Sun, PhD, Rhett Ketterling, Gary Hicks, Ph.D., C.L. Beach, PharmD, Peter L. Greenberg, MD, Elisabeth Paietta, PhD, Magdalena Czader, M.D., Ph.D., Janice Gabrilove, M.D., Harry P Erba, DM, PhD, Martin S. Tallman, MD, Steven D. Gore, M.D.
Journal: Blood
Blood (2010) 116 (21): 4013.
https://doi.org/10.1182/blood.V116.21.4013.4013
Published: 2010
Journal Articles

Outcome of Patients (pts) Treated for Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (s AML) After Azacitidine (AZA) Failure

Thomas Prebet, M.D., Ph.D., Steven D. Gore, M.D., Benjamin Esterni, Ph.D., Raphael Itzykson, Sylvain Thepot, C.L. Beach, PharmD, Pierre Fenaux, MD, PhD, Norbert Vey, MD
Journal: Blood
Blood (2010) 116 (21): 443.
https://doi.org/10.1182/blood.V116.21.443.443
Published: 2010
Journal Articles

Outcome of Relapse After Allogeneic Stem Cell Transplantation (SCT) In Patients with acute Myeloid Leukaemia (AML).

Raynier Devillier, Roberto Crocchiolo, Jr, Anne Etienne, MD, Thomas Prebet, M.D., Ph.D., Aude Charbonnier, Sabine Furst, Jean El Cheikh, Evelyne D’Incan, Jerome Rey, Catherine Faucher, Didier Blaise, MD, Norbert Vey, MD
Journal: Blood
Blood (2010) 116 (21): 4514.
https://doi.org/10.1182/blood.V116.21.4514.4514
Published: 2010
Journal Articles

Prolonged Administration of Azacitidine with or without Entinostat Increases Rate of Hematologic Normalization for Myelodysplastic Syndrome and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905

Thomas Prebet, M.D., Ph.D., Steven D. Gore, M.D., Zhuoxin Sun, PhD, Peter L. Greenberg, MD, Mark Juckett, MD, Lisa Malick, Mitchell R Smith, MD, PhD, Elisabeth Paietta, PhD, Magdalena Czader, Janice Gabrilove, M.D., Harry P Erba, DM, PhD, Martin S. Tallman, MD
Journal: Blood
Blood (2010) 116 (21): 601.
https://doi.org/10.1182/blood.V116.21.601.601
Published: 2010
Journal Articles

Lenalidomide (LEN) Combined to Intensive Chemotherapy (IC) In AML and Higher Risk MDS with Del 5q. Results of a Phase I/II Study of the Groupe Francophone Des Myelodysplasies (GFM)

Lionel Ades, Thomas Prebet, M.D., Ph.D., Aspasia Stamatoullas, Christian Recher, MD, PhD, Romain Guieze, Emmanuel Raffoux, Krimo Bouabdallah, Mathilde Hunault, Eric Wattel, Laure Stalnikiewicz, Andrea Toma, Herve Dombret, MD, Norbert Vey, Simone Boehrer, Claude Gardin, Pierre Fenaux, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 508.
https://doi.org/10.1182/blood.V116.21.508.508
Published: 2010